Objective Acute-onset diffuse interstitial lung disease (AoDILD) in patients with rheumatoid arthritis (RA) has been a serious concern, especially for those under treatment with biological agents which may affect the presentation and outcome of AoDILD, including Pneumocystis pneumonia (PCP). Therefore, we conducted a retrospective, multi-center study of AoDILD in RA patients receiving biological agents. Methods Patients who developed AoDILD while receiving biological agents (infliximab, etanercept, adalimumab and tocilizumab) were enrolled in the study. Definite PCP was defined as patients who showed either P. jirovecii organisms in their respiratory samples by microscopic examination, or positive tests for both P. jirovicii DNA-PCR with respiratory samples and an elevated serum 1,3-β-D-glucan level above the cut-off value. Probable PCP was defined as either a positive test for P. jirovicii PCR or an elevated serum β-D-glucan level. Chest HRCT findings were evaluated and scored by two board-certified radiologists. Results The final diagnoses for 26 patients examined were definite PCP for 13 patients, probable PCP for 11, and methotrexate-associated pneumonitis in 2 patients. Definite and probable PCP cases were clinically indistinguishable. Generalized, diffuse ground-glass opacity (GGO) is the characteristic HRCT finding in patients with definite or probable PCP, which was different from our previous findings in RA patients, mostly without biologics, showing GGO distributed in a panlobular or multilobular manner. The clinical outcome was favorable by treatment with trimethoprim-sulfamethoxazole and glucocorticoids.
Introduction
Rheumatoid arthritis (RA) is a chronic and erosive synovitis affecting multiple joints, leading to disability (1) . In addition to joint inflammation, RA shows many extraarticular manifestations. Among them, pulmonary diseases are not only common, but also regarded as very important prognostic factors (2, 3) . Especially, acute-onset diffuse interstitial lung diseases (AoDILD), including Pneumocystis pneumonia (PCP) and drug-induced pneumonitis, as well as acute exacerbation of interstitial lung disease due to RA itself, has long been a serious concern for clinical practice in RA because of its difficulty in diagnosis and considerable mortality.
Biological agents such as tumor necrosis factor (TNF) inhibitors brought about a paradigm shift in the treatment strategy for RA, in which even a clinical remission is a realistic therapeutic goal (1) . Along with the introduction of these drugs, the prevalence, cause, and outcome of AoDILD are likely to be altered, because cytokines targeted by those biological drugs play important roles in immunity against pathogenic organisms and also because drug-induced pneumonitis may occur as a result of these drugs. Indeed, postmarketing surveillance studies in Japan for all the patients treated with infliximab and etanercept suggested that PCP might be one of the major pulmonary complications in those patients with a frequency of 0.4% and 0.2%, respectively (4, 5) .
Despite the recent progress in diagnostic measures, a diagnosis of PCP in patients with RA remains a difficult task. Compared to patients with human immunodeficiency virus (HIV) infection, PCP in RA patients tends to develop abruptly and progress rapidly, and a positive test for P. jirovecii is rarely obtained by microscopic analysis of respiratory samples (6, 7) . One of the reasons for these differences may be that the amount of P. jirovecii organisms in the lungs is substantially less in PCP patients with RA (PCP-RA) compared to PCP patients with AIDS (AIDS-PCP) (8) (9) (10) ). Evaluation of the serum level of β-D-glucan as a subsidiary diagnostic tool has not been established (6, 7, 11, 12) .
Therefore, we conducted a retrospective, multi-center study of AoDILD in RA patients receiving biological agents approved in Japan (infliximab, etanercept, adalimumab, and tocilizumab). We investigated chest high resolution computed tomography (HRCT) findings as well as clinical records. Our results confirmed the predominance of PCP among AoDILD in RA patients receiving biological agents. In addition, we revealed some clinical and radiographic features of PCP-RA during biological therapy.
Patients and Methods

Patients
A total of 15 institutes in Japan with attending expert rheumatologists and pulmonologists participated in the present study. Patients who developed AoDILD while receiving biological agents which had been approved for RA in Japan by July 2009 (infliximab, etanercept, adalimumab and tocilizumab) were enrolled in the study. AoDILD was defined as acute onset and progression within a month, the presence of clinical signs and symptoms (fever, dry cough or dyspnea), hypoxia, and high-resolution computed tomography (HRCT) findings of bilateral, diffuse ground-glass opacities in the absence of cardiac failure (13, 14) . Patients who had previously been reported in the postmarketing surveillance of infliximab (4) or etanercept (5) were excluded from the study.
Diagnosis
A diagnosis of PCP was made according to the previously proposed diagnostic criteria for PCP with some modifications (6, 7) . Definite PCP was defined as AoDILD patients who showed either P. jirovecii microorganisms in their respiratory samples by microscopic examination, or positive tests for both P. jirovecii DNA polymerase chain reaction (PCR) (15, 16) with respiratory samples and an increased serum 1, 3-β-D-glucan level above the cut-off value previously reported by Tasaka et al (17) . Probable PCP was defined as those showing clinical manifestations compatible with PCP from either a positive test for P. jirovicii DNA PCR with respiratory samples or an increased serum β-Dglucan level above the cut-off value. Other patients were regarded as non-PCP (namely, those with pneumonia due to microorganisms other than P. jirovecii, drug-related pneumonitis or RA-associated interstitial lung disease).
Procedures
The surveillance sheets were filled out by contributing investigators according to the patients' medical records, then collected. Medical information included demographic features, co-morbidities, concomitant drugs, clinical manifestations, laboratory data, treatments and outcomes.
The measurement of serum β-D-glucan levels was performed either with the β-D-glucan test WAKO (Wako Pure Chemical Industries, Tokyo; n=10) or with the FUNGITEC G test MK (Seikagaku Corp., Tokyo; n=16).
The study protocol was approved by the Institutional Ethical Committee of the Social Health Insurance Central General Hospital, Tokyo. The guidelines of the Helsinki declaration and the ethical guidelines for epidemiologic research in Japan were strictly followed.
Evaluation of imaging findings
HRCT findings were evaluated and scored by two boardcertified radiologists (FS and TJ) with 32 and 27 years of experience in chest imaging, respectively, as previously described (18) . Ground glass opacity (GGO) was defined as faint opacity in which the underlying pulmonary vasculature was visible. Consolidation was defined as dense opacity obscuring the underlying pulmonary vasculature. Intralobular reticular opacity was defined as fine mesh-work opacity of less than 2 mm in size and interlobular septal thickening was defined as a thin line of 1 to 2 cm in length, continuing to a pulmonary vein or perpendicularly attached to the chest wall.
The extent of GGO and consolidation was subjectively scored in every ten percent in six locations (right upper lobe, right middle lobe, right lower lobe, upper division and lingual division of left upper lobe, and left lower lobe). GGO/consolidation scores were the sums of these six locations, thus the scores were 600 at maximum. Finally, HRCT patterns were classified into three pattern types. Type A: scattered sharply demarcated panlobular and/or multilobular GGO or consolidation; type B: constellation of ill-defined GGO or consolidation and distribution was not related to lobules; and type C: others (18) . Radiological findings were evaluated independently by the two chest radiologists and discussions were held to reach a consensus when interpretations differed.
Statistical analysis
The proportions of patients who met given criteria were compared with Fisher's exact test, while the mean values among groups were compared with the Kruskal-Wallis test or the Mann-Whitney U test. The relationships between variables were analyzed by the Spearman rank-order correlation test. Statistical significance was defined as p<0.05.
Results
PCP is the first choice of diagnosis for AoDILD in RA patients receiving biological agents
A total of 29 patients were enrolled in the study, and three patients were excluded from the analysis due to the lack of a chest HRCT examination, lack of sufficient clinical data, and judgment of an exacerbation of interstitial lung disease precedent to the introduction of biological treatment. As a result, the final diagnoses for the remaining 26 patients according to the criteria described above were definite PCP for 13 patients, probable PCP for 11, and others (MTXassociated pneumonitis; MTX-P (6)) in only two patients. It should be noted that all 11 patients diagnosed as probable PCP showed positive tests for P. jirovicii PCR with respiratory samples. Therefore, it was suggested that P. jirovecii was involved, at least in part, in most of the patients developing AoDILD during biological treatment for RA. Demographic features are shown in Table 1 .
Most of the patients were elderly females with longstanding RA. Importantly, they typically developed AoDILD within several months of successful biological treatment in addition to MTX and low-dose glucocorticoids. TNF inhibitors infliximab and etanercept were the predominant biological agents, chiefly because both adalimumab and tocilizumab had only been approved in Japan for RA in April 2008 (19) , and no patients treated with adalimumab were found in the present study.
We could not find any significant difference in demographic features between patients with definite PCP and those with probable PCP. Moreover, two MTX-P patients did not show apparent differences in their characteristics compared to patients with definite or probable PCP.
Definite and probable PCP showed comparable clinical presentation
Patients with definite PCP and those with probable PCP were compared in the subsequent analyses. Clinical signs and symptoms such as fever and dyspnea, as well as acute respiratory failure, were similarly observed between groups (Table 2) . Positive Diff-Quik staining and Grocott methenamine silver staining tests were obtained only in one patient each. Broncho-alveolar lavage (BAL) was performed in 12 definite PCP and 5 probable PCP patients. As expected by definition, the mean serum level of β-D-glucan was 141.9 pg/mL (range: 41.4-562.1 pg/mL) in definite PCP patients, which was almost ten times greater than 14.6 pg/ mL (range: !28.0 pg/mL) in those with probable PCP.
There were no significant differences between diagnostic groups in serum levels of sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6; (20) mean 609 U/mL in definite versus 458 U/mL in probable cases, respectively), surfactant protein-D (SP-D; (21) mean 156 ng/mL in definite versus 120 ng/mL in probable cases, respectively), immunoglobulin G (IgG), albumin (ALB), and C-reactive protein (CRP). The mean serum IgG concentration was higher than 1,000 mg/dL (Table 2) , and the mean peripheral lymphocyte count was higher than 1,000/μL (1,311 and 1,050 for definite and probable PCP, respectively) in both groups, which suggests that overall immunosuppression in those patients had been modest. Lymphocyte-predominant leukocytosis in BAL fluid was similarly observed between groups.
Generalized, diffuse GGO is the characteristic HRCT finding in patients with definite or probable PCP Next, we compared the HRCT findings between patients with definite PCP and those with probable PCP (Table 3) . The distribution of abnormal shadows on HRCT was similarly generalized in both groups (Fig. 1) . In addition, the sharpness of the border and the homogeneity of abnormal shadows were also comparable. HRCT patterns showed diffuse GGO distributed unrelatedly to lobules (type B GGO (6, 18)) in 9 of 13 (69.2%) patients with definite PCP and all 11 (100%) patients with probable PCP (Table 3) . This finding showed a marked contrast to our previous report on RA-PCP in which GGO distributed in panlobular or multilobular distribution (type A GGO (6, 18) ) was the pre- In addition, intralobular reticular opacity, representing both alveolar filling and interstitial changes (22) , was significantly frequent in patients with definite PCP compared to those with probable PCP. Moreover, the rate of a GGO score !300 was significantly higher in definite PCP patients than in those with probable PCP (100% versus 54.5%; p<0.01), although the mean value of GGO scores was not significantly different between groups.
Furthermore, consolidation scores were significantly higher in definite PCP patients than in those with probable PCP. Concordantly, infiltration scores correlated with the serum level of β-D-glucan (R=0.47, p<0.05) but not with KL-6 (R=0.19, p=0.38), while GGO scores did not correlate with the serum level of β-D-glucan (R=0.20, p=0.35) and KL-6 (R=0.1, p=0.74). Thus, the chest HRCT from patients with definite PCP showed more intense abnormality in some aspects than that from probable PCP patients.
Two MTX-P patients did not show apparent differences in their HRCT findings compared to patients with definite or probable PCP. The HRCT patterns also showed diffuse GGO with distribution unrelated to lobules (type B GGO) in both patients. Therefore, it might be difficult to distinguish MTX-P from PCP in RA patients receiving biological agents solely by the chest HRCT findings (Fig. 1 ).
Favorable outcome in PCP patients with RA receiving biological agents
Finally, the treatments and responses to them were compared between patients with definite and probable PCP (Table 4). Severity, defined by the requirement of oxygen supplementation or mechanical ventilation, was not significantly different between groups.
Trimethoprim-sulfamethoxazole (TMP-SMX) was given to all patients with definite or probable PCP. However, adverse events with TMP/SMX such as gastrointestinal and hematological disorders were commonly observed at an approximate rate of two-thirds in the patients. Consequently, more than one-third of the patients could not complete TMP/SMX treatment. Nonetheless, the final outcome of PCP under biological treatment was acceptable with death in only one patient with definite PCP.
In addition to TMP-SMX, moderate-to high-dose glucocorticoids, including intravenous pulse methylprednisolone (IV-MP), were administered to most of the patients with definite or probable PCP. Both of the patients with MTX-P only received IV-MP and subsequent moderate-dose glucocorticoids but not TMP-SMX, which was successful in both patients. 
Discussion
In the present study, we found that PCP prevails in RA patients who develop AoDILD while receiving biological agents. Definite PCP and probable PCP, eventually based on the serum level of β-D-glucan, showed similar clinical presentations; the same HRCT findings, including predominantly type B GGO (GGO distributed unrelated to lobules), although definite PCP patients showed more intense HRCT findings than probable PCP patients in some aspects, such as the presence of intralobular reticular opacity, the rate of patients with a GGO score !300, and consolidation scores; and favorable clinical outcomes.
Among the 26 patients enrolled in this study, only two MTX-P patients were excluded from a diagnosis as definite or probable PCP. We could not completely avoid possible selection biases. However, the predominant reason why most patients were diagnosed as having definite or probable PCP lies with the definitions of these. If we had exclusively selected patients showing positive tests for Diff-Quik or Grocott staining, then only two patients could meet such diagnostic criteria for PCP. However, the diagnostic criteria based on patients with AIDS or similarly immunocompromised patients did not seem to be appropriate for patients with autoimmune diseases, including RA showing only a modest immunocompromised state (6, 7) . This difference in immune status between RA and AIDS led to a ten-fold difference in the serum β-D-glucan level in our previous study (6) .
We used the recently proposed diagnostic criteria and cutoff level for serum β-D-glucan (17) . However, our results did not show a clear distinction between definite and probable PCP in view of clinical and radiographic features. Thus, it is likely that a significant portion of probable PCP patients in this study were indeed complicated by PCP, sug- gesting that the cut-off value for serum β-D-glucan for a diagnosis of RA-PCP could be set at a lower level than that used in the present study, although a higher cut-off value (100 pg/mL) for serum β-D-glucan has been proposed for patients with AIDS or hematological malignancy (23) .
Another possible diagnosis for patients with probable PCP is interstitial pneumonia associated with RA itself. It should be noted that most patients showed remission or low disease activity with biological agents and a stable dose of precedent MTX (Table 1 ) during the development of AoDILD. Therefore, we assume that the contribution of RA itself and MTX may be limited in the present patients. The possible association of infliximab or etanercept with interstitial pneumonia has been reported. Postmarketing surveillance revealed a prevalence of interstitial pneumonia of 0.5% and 0.6% of patients treated with infliximab and etanercept, respectively (4, 5) . However, PCP patients might have been erroneously included in that prevalence due to a lack of appropriate examinations such as P. jirovecii-PCR.
Interestingly, the predominant HRCT pattern was type B GGO in both definite and probable PCP patients, as well as MTX-P patients. In our previous study, type B GGO prevailed in AIDS-PCP, while type A GGO prevailed in MTX-P (6). And type A GGO and type B GGO were similarly observed in RA-PCP patients mostly without biological agents. Assuming that the HRCT patterns reflect the corresponding pathophysiology of the lungs, then RA-PCP patients with biologics may stand between RA-PCP (without biological agents) and AIDS-PCP. This hypothesis parallels the fact that the mean serum β-D-glucan level of definite PCP in RA with biological agents (141.9 pg/mL) in the present study was between RA-PCP (98.5 pg/mL) and AIDS-PCP (969.5 pg/mL) in our previous study (6) .
When we considered the association of a certain biological agent with a certain radiological finding, we noticed that two patients receiving tocilizumab showed a type A GGO pattern in chest HRCT findings. One patient each from those receiving infliximab and etanercept demonstrated type A GGO. Otherwise, we could not find any radiographic differences among the three biological agents.
The reason why definite PCP patients showed more intense HRCT findings than probable PCP patients in some aspects has not been determined. Concordantly, several clinical findings, such as lymphocytosis in BAL fluids and an elevated rate of serum KL-6 and SP-D (Table 2 ), tended to be more pronounced in definite PCP than in probable PCP, although the differences were not statistically significant. Importantly, the serum level of KL-6 as well as that of SP-D was within the normal range in approximately 40% and 70% of definite and probable PCP patients, respectively (Table 2), which was consistent with a recent report on the lower detection rates of serum KL-6 levels, as well as β-Dglucan, in non-HIV PCP than in AIDS-PCP (24) .
Nevertheless, the clinical outcome was favorable in both definite and probable PCP patients, as well as in the two MTX-P patients, except for one patient whose condition had been fatal due to reasons other than PCP itself (Table 4) . This good outcome was accomplished despite the fact that more than one-third of patients could not complete the recommended dose of TMP/SMX treatment for AIDS-PCP (25) because of serious adverse effects. Taking this fact and less organism burden than AIDS-PCP into consideration, a reduced dose of TMP/SMX (6 tablets per day, for example) may be sufficient for RA-PCP patients with biological agents. This treatment strategy should be validated by a prospective, randomized, controlled study in the near future.
In conclusion, the possibility of PCP should be intensively investigated for RA patients developing AoDILD while receiving biologics. Chest HRCT findings were typically GGO distributed in a non-panlobular manner (type B GGO), especially in those receiving anti-TNF biological agents. The overall clinical outcome was favorable with a treatment of TMP/SMX and glucocorticoids. 
